The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.
Open accessAbstract
The aim of this study was to compare the ability of both a 55- and 75-kD soluble tumor necrosis factor receptor immunoglobulin G fusion protein (sTNFR-IgG) in protecting against death in a murine model of gram-negative sepsis. Pretreatment with 250 micrograms of the p75 construct delayed but did not avert death in this model, reducing peak bioactive TNF-alpha levels after infection from 76.4 ng ml-1 in control mice to 4.7 ng ml-1 in the treated group (p < 0.05, two-sample t test). However, these low levels of bioactive TNF-alpha persisted in the p75 fusion protein-treated animals compared with the controls and were sufficient to mediate delayed death. In contrast, pretreatment with 200 micrograms of the p55 sTNFR-IgG gave excellent protection against death with complete neutralization of circulating TNF. Studies of the binding of TNF-alpha with the soluble TNFR fusion proteins showed that the p75 fusion construct exchanges bound TNF-alpha about 50-100-fold faster than the p55 fusion protein. Thus, although both fusion proteins in equilibrium bind TNF-alpha with high affinity, the TNF-alpha p55 fusion protein complex is kinetically more stable than the p75 fusion construct, which thus acts as a TNF carrier. The persistent release of TNF-alpha from the p75 fusion construct limits its therapeutic effect in this model of sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shock and Tissue Injury Induced by Recombinant Human Cachectin
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., & Cerami, A. (1987) · Nature · doi:10.1038/330662a0 · Cited by 2,448 · cited 1×
“A number of reagents have been developed to neutralize TNF-c~ activity, mAbs to TNF-c~ have shown good activity in a number of animal models of experimental sepsis and are currently undergoing clinical trials (22, 23).”
BackgroundDetection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677 · cited 1×
“Principal among these is TNF-ot, a cytokine produced mainly by activated macrophages, which is able in purified form to reproduce nearly all of the features of sepsis and septic shock (3, 4).”
BackgroundPfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M., & Mak, T. W. (1993) · Cell · doi:10.1016/0092-8674(93)90134-c · Cited by 1,677
Cited by
Opal, S. M., & DePalo, V. A. (2000) · Chest · doi:10.1378/chest.117.4.1162 · Cited by 1,752
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future
Mann, D. L. (2002) · Circulation Research · doi:10.1161/01.res.0000043825.01705.1b · Cited by 988
Schmidt, E. P., Yang, Y., Janssen, W. J., Gandjeva, A., Perez, M. J., Barthel, L., Zemans, R. L., Bowman, J. C., Koyanagi, D. E., Yunt, Z. X., et al. (2012) · Nature Medicine · doi:10.1038/nm.2843 · Cited by 848
Tumor necrosis factor in the heart
Meldrum, D. R. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.3.r577 · Cited by 746
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Anti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
Oxidative stress and left ventricular remodelling after myocardial infarction
Hori, M., & Nishida, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn335 · Cited by 523
The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor
Grell, M., Wajant, H., Zimmermann, G., & Scheurich, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.570 · Cited by 478
TNF-α suppresses the expression of clock genes by interfering with E-box-mediated transcription
Cavadini, G., Petrzilka, S., Kohler, P., Jud, C., Tobler, I., Birchler, T., & Fontana, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701466104 · Cited by 421
King, M. A., Covassin, L., Brehm, M. A., Racki, W., Pearson, T., Leif, J., Laning, J., Fodor, W., Foreman, O., Burzenski, L., et al. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 386
Inflammatory responses in Ebola virus-infected patients
BAIZE, S., LEROY, E. M., GEORGES, A. J., GEORGES-COURBOT, M.-C., CAPRON, M., BEDJABAGA, I., LANSOUD-SOUKATE, J., & MAVOUNGOU, E. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01800.x · Cited by 370
Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis
Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 341
Abraham, E., Laterre, P.-F., Garbino, J., Pingleton, S., Butler, T., Dugernier, T., Margolis, B., Kudsk, K., Zimmerli, W., Anderson, P., et al. (2001) · Critical Care Medicine · doi:10.1097/00003246-200103000-00006 · Cited by 293
Self-citationThe potential biological and clinical significance of the soluble tumor necrosis factor receptors
Aderka, D. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00026-3 · Cited by 285
Hack, C. E., Aarden, L. A., & Thus, L. G. (1997) · Advances in Immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 280
van der Poll, T., Endert, E., Coyle, S. M., Agosti, J. M., & Lowry, S. F. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.2.r357 · Cited by 27
Metadata
- Authors
- Evans, T. J., Moyes, D., Carpenter, A., Martin, R., Loetscher, H., Lesslauer, W., & Cohen, J.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-12-01
- Volume
- 180
- Issue
- 6
- Pages
- 2173-2179
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2108491756
- Cited by
- 174
- References
- 4
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.